MDRX (Veradigm) Change In Receivables: $9.5 Mil (TTM As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDRX Veradigm Inc MDRX
23 GF Score
Price $4.90
View Full Analysis

What is Veradigm Change In Receivables?

Veradigm MDRX +1.87% 23 Change In Receivables is $9.5 Mil as of Dec. 2022. GuruFocus rates MDRX with a GF Score™ of 23/100.

Veradigm's change in receivables for the quarter that ended in Dec. 2022 was $9.5 Mil. It means Veradigm's Accounts Receivable declined by $9.5 Mil from Dec. 2021 to Dec. 2022 .

Veradigm's change in receivables for the fiscal year that ended in Dec. 2022 was $9.5 Mil. It means Veradigm's Accounts Receivable declined by $9.5 Mil from Dec. 2021 to Dec. 2022 .

Veradigm's Accounts Receivable for the quarter that ended in Dec. 2022 was $119.1 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Veradigm's Days Sales Outstanding for the six months ended in Dec. 2022 was 36.98.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Veradigm's liquidation value for the six months ended in Dec. 2022 was $48.7 Mil.

Veradigm  (OTCPK:MDRX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Veradigm's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=119.147/588.017*91
=36.98

2. In Ben Graham's calculation of liquidation value, Veradigm's accounts receivable are only considered to be worth 75% of book value:

Veradigm's liquidation value for the quarter that ended in Dec. 2022 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=446.593-487.217+0.75 * 119.147+0.5 * 0
=48.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veradigm Change In Receivables Related Terms

Veradigm Change In Receivables Historical Data

* Premium members only.

The historical data trend for Veradigm's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veradigm Change In Receivables Chart

Veradigm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.43 78.17 -0.26 9.55 0.00

Veradigm Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 May09 May10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.43 78.17 -0.26 9.55 0.00
MDRX
23GF Score
Veradigm Inc MDRX
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veradigm Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2022 was $9.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $9.5 Mil mean?
Veradigm (MDRX) has a Change In Receivables of $9.5 Mil as of Dec. 2022. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Veradigm and its competitors.
Is Veradigm's Change In Receivables too high?
Veradigm's current Change In Receivables is $9.5 Mil. Overall, Veradigm has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's Change In Receivables compare to WEAV and PHR?
Veradigm's Change In Receivables of $9.5 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Healthcare Providers & Services company?
A good Change In Receivables depends on the Healthcare Providers & Services industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Veradigm and its competitors. Veradigm's current Change In Receivables is $9.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (MDRX) has a current Change In Receivables of $9.5 Mil. The current Change In Receivables is $9.5 Mil. Veradigm's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Veradigm (MDRX), the current Change In Receivables is $9.5 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veradigm Business Description

Address 222 Merchandise Mart Plaza, Suite 2024, Chicago, IL, USA, 60654
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
23GF Score

Get the complete analysis for MDRX

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.90
Price